Acromegaly

Genetically Modified Growth Hormone May Offer Hope for Treatment

Published in Drug Week, May 5th, 2000

According to a study published in the April 19, 2000, edition of the New England Journal of Medicine, an investigational drug for the treatment of acromegaly was effective in 89% of patients and was well tolerated.

Somavert (pegvisomant for injection), manufactured by Sensus, is designed to block the effects of excessive growth hormone production by a pituitary tumor.

"Somavert holds tremendous promise as a new treatment option for patients with acromegaly," said endocrinologist and co-author Anne Klibanski, MD, Massachusetts General Hospital and Harvard Medical School. "This new therapy significantly improved the clinical signs and symptoms...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2000-05-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry